Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study)
Background The recent introduction of biological drugs specifically targeting the interleukins involved in psoriasis pathogenesis revolutionized the therapeutic scenario of moderate to severe forms of psoriasis. Among these, risankizumab, an anti-IL-23, was shown to be effective both in clinical tri...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Journal of Dermatological Treatment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/09546634.2024.2358150 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850115094306881536 |
|---|---|
| author | Diego Orsini Chiara Assorgi Claudio Bonifati Norma Cameli Dario Graceffa Luca Potestio Matteo Megna |
| author_facet | Diego Orsini Chiara Assorgi Claudio Bonifati Norma Cameli Dario Graceffa Luca Potestio Matteo Megna |
| author_sort | Diego Orsini |
| collection | DOAJ |
| description | Background The recent introduction of biological drugs specifically targeting the interleukins involved in psoriasis pathogenesis revolutionized the therapeutic scenario of moderate to severe forms of psoriasis. Among these, risankizumab, an anti-IL-23, was shown to be effective both in clinical trials and real-life experiences. However, data on its use on very severe forms of psoriasis, defined by a Psoriasis Area Severity Index (PASI) of at least 30, are scant. In this context, our study aimed to investigate the outcomes of patients with very severe psoriasis, and the involvement of difficult-to-treat areas treated with risankizumab for up to 2 years.Methods A retrospective, observational study enrolled patients with very severe plaque psoriasis and the involvement of difficult-to-treat areas undergoing treatment with risankizumab. Clinical and demographic data were collected at baseline. Moreover, at baseline and each dermatological examination (16, 28, 40 and 104 weeks), clinical improvement was measured using the percentage of patients achieving PASI 75/90/100 response, site-specific Psoriasis Global Assessment and Dermatology Life Quality Index.Results At baseline, the mean PASI was 35.1 ± 5.1. A significant reduction was observed since week 16 and maintained up to week 104. Moreover, the Psoriasis Global Assessment and Dermatology Life Quality Index improved as well.Conclusions Risankizumab showed to be effective and safe in patients affected by very severe forms of psoriasis with the involvement of difficult-to-treat areas. |
| format | Article |
| id | doaj-art-aab4dd33cb954318b975b155cc0a5f99 |
| institution | OA Journals |
| issn | 0954-6634 1471-1753 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Journal of Dermatological Treatment |
| spelling | doaj-art-aab4dd33cb954318b975b155cc0a5f992025-08-20T02:36:40ZengTaylor & Francis GroupJournal of Dermatological Treatment0954-66341471-17532024-12-0135110.1080/09546634.2024.2358150Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study)Diego Orsini0Chiara Assorgi1Claudio Bonifati2Norma Cameli3Dario Graceffa4Luca Potestio5Matteo Megna6Department of Clinical Dermatology, San Gallicano Dermatological Institute, IRCCS, Rome, ItalySection of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalyDepartment of Clinical Dermatology, San Gallicano Dermatological Institute, IRCCS, Rome, ItalyDepartment of Clinical Dermatology, San Gallicano Dermatological Institute, IRCCS, Rome, ItalyDepartment of Clinical Dermatology, San Gallicano Dermatological Institute, IRCCS, Rome, ItalySection of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalySection of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, ItalyBackground The recent introduction of biological drugs specifically targeting the interleukins involved in psoriasis pathogenesis revolutionized the therapeutic scenario of moderate to severe forms of psoriasis. Among these, risankizumab, an anti-IL-23, was shown to be effective both in clinical trials and real-life experiences. However, data on its use on very severe forms of psoriasis, defined by a Psoriasis Area Severity Index (PASI) of at least 30, are scant. In this context, our study aimed to investigate the outcomes of patients with very severe psoriasis, and the involvement of difficult-to-treat areas treated with risankizumab for up to 2 years.Methods A retrospective, observational study enrolled patients with very severe plaque psoriasis and the involvement of difficult-to-treat areas undergoing treatment with risankizumab. Clinical and demographic data were collected at baseline. Moreover, at baseline and each dermatological examination (16, 28, 40 and 104 weeks), clinical improvement was measured using the percentage of patients achieving PASI 75/90/100 response, site-specific Psoriasis Global Assessment and Dermatology Life Quality Index.Results At baseline, the mean PASI was 35.1 ± 5.1. A significant reduction was observed since week 16 and maintained up to week 104. Moreover, the Psoriasis Global Assessment and Dermatology Life Quality Index improved as well.Conclusions Risankizumab showed to be effective and safe in patients affected by very severe forms of psoriasis with the involvement of difficult-to-treat areas.https://www.tandfonline.com/doi/10.1080/09546634.2024.2358150PsoriasisrisankizumabPASIIL-23 inhibitorimmonumodulatory therapiesinflammatory skin diseases |
| spellingShingle | Diego Orsini Chiara Assorgi Claudio Bonifati Norma Cameli Dario Graceffa Luca Potestio Matteo Megna Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study) Journal of Dermatological Treatment Psoriasis risankizumab PASI IL-23 inhibitor immonumodulatory therapies inflammatory skin diseases |
| title | Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study) |
| title_full | Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study) |
| title_fullStr | Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study) |
| title_full_unstemmed | Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study) |
| title_short | Effectiveness and safety of risankizumab in VEry severe plaque psoriasis: a real-life retrospective study (VESPA-Study) |
| title_sort | effectiveness and safety of risankizumab in very severe plaque psoriasis a real life retrospective study vespa study |
| topic | Psoriasis risankizumab PASI IL-23 inhibitor immonumodulatory therapies inflammatory skin diseases |
| url | https://www.tandfonline.com/doi/10.1080/09546634.2024.2358150 |
| work_keys_str_mv | AT diegoorsini effectivenessandsafetyofrisankizumabinverysevereplaquepsoriasisarealliferetrospectivestudyvespastudy AT chiaraassorgi effectivenessandsafetyofrisankizumabinverysevereplaquepsoriasisarealliferetrospectivestudyvespastudy AT claudiobonifati effectivenessandsafetyofrisankizumabinverysevereplaquepsoriasisarealliferetrospectivestudyvespastudy AT normacameli effectivenessandsafetyofrisankizumabinverysevereplaquepsoriasisarealliferetrospectivestudyvespastudy AT dariograceffa effectivenessandsafetyofrisankizumabinverysevereplaquepsoriasisarealliferetrospectivestudyvespastudy AT lucapotestio effectivenessandsafetyofrisankizumabinverysevereplaquepsoriasisarealliferetrospectivestudyvespastudy AT matteomegna effectivenessandsafetyofrisankizumabinverysevereplaquepsoriasisarealliferetrospectivestudyvespastudy |